Radical prostatectomy or external beam radiotherapy
Open Access
- 11 July 2002
- Vol. 95 (2) , 215-218
- https://doi.org/10.1002/cncr.10659
Abstract
D'Amico et al. hypothesized that “low‐risk” and low biopsy tumor volume “intermediate‐risk” patients who are treated with RP fare significantly better than patients treated with conventional‐dose RT. However, patient selection and the choice of end points as well as the use of low dose radiation leaves this issue unresolved. See also pages 211–4 and 281–6.Keywords
This publication has 12 references indexed in Scilit:
- Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen eraCancer, 2002
- DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?Journal of Urology, 2001
- Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate CancerJAMA, 2000
- Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparisonInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trialsInternational Journal of Radiation Oncology*Biology*Physics, 2000
- 2135 3D conformal radiotherapy improves PSA failure rates for intermediate risk patients at conventional dosesInternational Journal of Radiation Oncology*Biology*Physics, 1999
- THE DURABILITY OF EXTERNAL BEAM RADIATION THERAPY FOR PROSTATE CANCER: CAN IT BE IDENTIFIED?Journal of Urology, 1999
- Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1999
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate CancerJAMA, 1998